$30.12
-0.40 (-1.31%)
Open$30.35
Previous Close$30.52
Day High$30.70
Day Low$30.10
52W High$44.00
52W Low$19.50
Volume—
Avg Volume35.1K
Market Cap122.58M
P/E Ratio—
EPS$-1.06
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+11.4% upside
Current
$30.12
$30.12
Target
$33.56
$33.56
$24.17
$33.56 avg
$46.23
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 687.2K | 1.09M | 10.43M |
| Net Income | -12,476,417 | -17,738,981 | 2.46M |
| Profit Margin | -1,815.3% | -1,724.6% | 23.6% |
| EBITDA | -16,273,435 | -24,423,006 | 3.49M |
| Free Cash Flow | — | — | 3.25M |
| Rev Growth | -36.7% | -36.7% | +12.7% |
| Debt/Equity | — | — | 1.45 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $263.29 | -1.12% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $423.64 | +1.32% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $151.28 | -0.61% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $526.73 | -0.18% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $750.51 | -0.23% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $254.07 | -0.51% | 41.4 | 33.44B |